LENZ Therapeutics, Inc. (LENZ) Research

LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.

Market snapshot

Symbol
LENZ
Price
$6.15
Day change
-3.00%
Market cap
$192.8M
P/E ratio
-1.77x
52-week range
5.84-50.4
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 1 month
Analyst price target
$12.00

Recent news

  • LENZ Therapeutics adds China partner for presbyopia drug VIZZ

    LENZ Therapeutics, Inc. (NASDAQ:LENZ) said Everest Medicines has acquired the rights to develop and commercialize VIZZ, also known as LNZ100, in Greater China. Under the agreement, Everest Medicines (HKEX:1952) takes on development and commercialization of the drug in the Greater China market, LENZ said.

Peer companies

  • Arbutus Biopharma Corporation (ABUS)
  • Geron Corporation (GERN)
  • GH Research PLC (GHRS)
  • Maravai LifeSciences Holdings, Inc. (MRVI)
  • Nanobiotix S.A. (NBTX)
  • Prime Medicine, Inc. (PRME)
  • Rezolute, Inc. (RZLT)
  • ARS Pharmaceuticals, Inc. (SPRY)

Recent insider activity

  • RA CAPITAL MANAGEMENT, L.P. — A-Award (22100 shares) on 2026-06-15
  • George Jeffrey P. — A-Award (22100 shares) on 2026-06-15
  • Drapkin Kimberlee C — A-Award (22100 shares) on 2026-06-15
  • MCCOLLUM JAMES W — A-Award (22100 shares) on 2026-06-15
  • Thunen Shelley B — A-Award (22100 shares) on 2026-06-15

Open LENZ Therapeutics, Inc. (LENZ) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.